ADARx Pharmaceuticals
Tracked across 2 events · 12 articles · First seen Sep 21, 2026 · Last active Sep 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
ADARx Pharmaceuticals, a San Diego-based developer of RNA-based drugs for rare immune, kidney, cardiovascular and neurological diseases, announced on September 21, 2026 that it is seeking a valuation of up to $1.74 billion in its…
Impact: The central entity of the event, seeking up to $1.74 billion valuation and $371.9 million in proceeds via a Nasdaq listing under ADRX. A successful IPO would fund late-stage trials of onvuzosiran and validate its RNA drug platform.
Sep 21, 2026 · 6 articles
Business
Iambic Therapeutics, a San Diego-based drug developer backed by Nvidia and the Qatar Investment Authority, filed for a US initial public offering on Monday, September 21, 2026, aiming to list on the Nasdaq under the…
Impact: Launched its IPO roadshow the same day, part of the busy fall biotech listing slate.
Sep 21, 2026 · 6 articles
95
ADARx Pharmaceuticals sought IPO valuationADARx Pharmaceuticals $1.74B US IPO
80
AbbVie agreed to invest ADARx PharmaceuticalsADARx Pharmaceuticals $1.74B US IPO
60
ADARx Pharmaceuticals planned Nasdaq listing NasdaqADARx Pharmaceuticals $1.74B US IPO
25
ADARx Pharmaceuticals launched roadshowIambic Therapeutics Files...
ERGEN INTELLIGENCE
Track ADARx Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard